Hudson Bay Capital Management LP Sells 49,382 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Hudson Bay Capital Management LP reduced its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 12.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 345,952 shares of the company’s stock after selling 49,382 shares during the period. Hudson Bay Capital Management LP owned 0.69% of Immunocore worth $10,856,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of IMCR. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Immunocore by 4,696.3% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after buying an additional 1,268 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new stake in Immunocore during the second quarter worth about $42,000. State of Tennessee Department of Treasury bought a new position in shares of Immunocore during the second quarter valued at approximately $132,000. Skandinaviska Enskilda Banken AB publ bought a new position in shares of Immunocore during the second quarter valued at approximately $248,000. Finally, Lido Advisors LLC purchased a new position in shares of Immunocore during the second quarter valued at approximately $255,000. 84.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on IMCR. Jefferies Financial Group initiated coverage on Immunocore in a research report on Monday, August 25th. They set a “buy” rating and a $48.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research report on Wednesday, October 22nd. Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 4th. Morgan Stanley boosted their target price on shares of Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Finally, Guggenheim initiated coverage on Immunocore in a research note on Thursday, September 18th. They issued a “neutral” rating on the stock. Seven equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Immunocore presently has an average rating of “Moderate Buy” and a consensus target price of $61.00.

Immunocore Price Performance

Shares of Immunocore stock opened at $36.80 on Monday. The firm has a market cap of $1.86 billion, a PE ratio of -64.56 and a beta of 0.76. The stock has a 50 day moving average of $35.30 and a 200 day moving average of $34.50. The company has a current ratio of 6.00, a quick ratio of 5.97 and a debt-to-equity ratio of 0.99. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $40.71.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.32. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The business had revenue of $103.69 million for the quarter, compared to analysts’ expectations of $137.29 million. During the same period in the prior year, the firm earned $0.17 EPS. The company’s revenue for the quarter was up 29.2% on a year-over-year basis. On average, research analysts expect that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.